Whole-body biodistribution and radiation dosimetry estimates for the β-amyloid radioligand [ 11 C]MeS-IMPY in non-human primates

Similar documents
Amira K. Brown, Ph.D. Molecular Imaging Branch, NIMH Bldg. 1 Rm. B3-10

Austin Radiological Association Ga-68 NETSPOT (Ga-68 dotatate)

Austin Radiological Association Nuclear Medicine Procedure PET SODIUM FLUORIDE BONE SCAN (F-18 NaF)

Lu-DOTATATE PRRT dosimetry:

Use Of MCNP With Voxel-Based Image Data For Internal Dosimetry Applications

JHM-IRB Guidelines for Radiation Statements

Page 1 of CONTRAINDICATIONS None (4)

FAX, A FEMALE ADULT VOXEL PHANTOM FOR RADIATION PROTECTION DOSIMETRY

Radiation Dosimetry for CT Protocols

Comparison of organ doses estimations in radiology with PCXMC application based on MIRD phantoms and CALDose-X application based on voxel phantoms

Radiation Protection Program Update: The Details. July 2010

SUMMARY OF PRODUCT CHARACTERISTICS. for. BRIDATEC, kit for radiopharmaceutical preparation

IART and EBRT, an innovative approach

A Probabilistic Approach for the Assessment of Internal Dose to Chronic Lymphocytic Leukemia Precursor Cells

Measurement of organ dose in abdomen-pelvis CT exam as a function of ma, KV and scanner type by Monte Carlo method

Radiation Dose to Patients from Radiopharmaceuticals

A Real-Time Monte Carlo System for Internal Dose Evaluation Using an Anthropomorphic Phantom with Different Shapes of Tumors Inserted

Austin Radiological Association Nuclear Medicine Procedure THYROID UPTAKE MEASUREMENT (I-123 or I-131 as Sodium Iodide)

Assessment of effective dose in paediatric CT examinations

Skyscan 1076 in vivo scanning: X-ray dosimetry

To report suspected adverse reactions to Axumin, call AXUMIN1 ( ) or contact FDA at FDA-1088 or

Core SPC for Fludeoxyglucose ( 18 F) March 2005

Impact of ICRP-89 Based Models on Dose Estimates for Radiopharmaceuticals and CT Exams

The Management of Imaging Procedure Dose Nuclear Medicine Dose Indices

PHYTACIS. Kit for the preparation of technetium [ 99m Tc] phytate injection USER PACKAGE LEAFLET

Palliative treatment of bone metastases with samarium-153

Radiation Safety Information for Students in Courses given by the Nuclear Physics Group at KTH, Stockholm, Sweden

FP/1-61//- p-o37 A mb. Precision Nuclear, LLC. July 7, 2011

Several different radiopharmaceuticals have been used in

Positron Emission Tomography: Tool to Facilitate Drug Development and to Study Pharmacokinetics

TECHNESCAN SESTAMIBI NAME OF THE MEDICINE DESCRIPTION. Kit for the preparation of Technetium [ 99m Tc] Sestamibi Injection

Sodium Iodide I 131 Solution. Click Here to Continue. Click Here to Return to Table of Contents

Dosimetry of recently introduced CBCT Units for Oral and Maxillofacial Radiology

Targeted Alpha Particle Therapy: Imaging, Dosimetry and Radiation Protection

Erasmus Experience. Lu-DOTA-octreotate PRRT

Sodium Fluoride F 18 Injection* PET/CT Imaging

MATERIALS AND METHODS Synthesis

INTEREST GRABBER NOTEBOOK #1

Impact of ICRP-89 Based Models on Dose Estimates for Radiopharmaceuticals and CT Exams. Stabin MG, Kost SD, Clark JH, Pickens DR, Price RR, Carver DE

The estimated absorbed doses from a bolus intravenous

Positron Emission Tomography: Tool to Facilitate Drug Development and to Study Pharmacokinetics

MT09 - Normal Human Tissue Microarray, FDA

Machine Learning Powered Automatic Organ Classification for Patient Specific Organ Dose Estimation

Unit 3 Lesson 5 How Do Our Bodies Digest Food, Remove Wastes, and Send Messages? Copyright Houghton Mifflin Harcourt Publishing Company

GALLIUM CITRATE Ga 67 INJECTION

Dosimetry (Dose Estimation) of Internal Emitters. Outline. For Radiation Effects, is Dose the only Answer? Estimation of Dose and not Dosimetry

SUPPORTING INFORMATION. Target-or-Clear Zirconium-89 Labeled Silica Nanoparticles for. Enhanced Cancer-Directed Uptake in Melanoma: A Comparison

Individualised Treatment Planning for Radionuclide therapy (Molecular Radiotherapy)

AN INTRODUCTION TO NUCLEAR MEDICINE

Medical Physics 4 I3 Radiation in Medicine

Theragnostics for bone metastases. Glenn Flux Royal Marsden Hospital & Institute of Cancer Research Sutton UK

ALTERNATIVES TO THE EFFECTIVE DOSE FOR STOCHASTIC RISK ASSESSMENT IN MEDICAL IMAGING

DRAXIMAGE SODIUM IODIDE I 131 CAPSULES, USP DIAGNOSTIC. For Oral Use DESCRIPTION

Austin Radiological Association Nuclear Medicine Procedure SPHINCTER OF ODDI STUDY (Tc-99m-Mebrofenin)

The sentinel lymph node (SLN) technique has proven

Standardization of Radiopharmaceutical Dosimetry

GLUCEPTATE. Technetium Tc 99m Gluceptate Kit DIAGNOSTIC DESCRIPTION

Downloaded from by guest on 18 November 2018

Radiation Dose Rates from Patients Administrated Radiopharmaceuticals Used for Brain Blood Flow Investigation.

Validation of gallbladder absorbed radiation dose reduction simulation: human dosimetry of [ 18 F]fluortriopride

Austin Radiological Association BRAIN AMYLOID STUDY (F-18-Florbetapir)

Core Summary of Product Characteristics for Fludeoxyglucose ( 18 F)

Clinical Implementation of patient-specific dosimetry, comparison with absorbed fraction-based method

OVARIES URETER FALLOPIAN TUBES BLADDER UROGENITAL OPENINGS (BOTH SEXES) PENIS VAGINA UTERUS

Health Concerns Related to Radiation Exposure. of the Female Nuclear Medicine Patient. Michael G. Stabin

DRAXIMAGE SODIUM IODIDE I 131 SOLUTION USP DIAGNOSTIC. For Oral Use DESCRIPTION

IMPC phenotyping SOPs in JMC

weighing risks against benefits ALARA principle appropriate activities (radiopharmaceutical doses)

Click Here to Continue. Click Here to Return to Table of Contents

Plutonium Worker Dosimetry

BIO 137 Human Anatomy & Physiology I. Laboratory Manual. Laboratory #1: Measurements, Body Organization and Anatomical Systems

Radiopharmaceuticals. Radionuclides in NM. Radionuclides NUCLEAR MEDICINE. Modes of radioactive decays DIAGNOSTIC THERAPY CHEMICAL COMPOUND

Austin Radiological Association Nuclear Medicine Procedure THERAPY FOR THYROID CANCER (I-131 as Sodium Iodide)

Coronary artery disease is a major cause of death in

Estimating Testicular Cancer specific Mortality by Using the Surveillance Epidemiology and End Results Registry

Click Here to Continue. Click Here to Return to Table of Contents

Optimization of a routine method for bone marrow dose estimation in

Chapter 13 worksheet

Summary of Product Characteristics

OSTEOCIS 3 mg kit for radiopharmaceutical preparation

Population Collective Effective Dose from Nuclear Medicine procedures in Greece

Estimation of Effective Doses for Radiation Cancer Risks on ISS, Lunar and Mars Missions with Space Radiation Measurements

Value of PET/CT in Initial Staging and Subsequent Treatment Strategy for Metastatic Breast Cancer

Epidemiology in Texas 2006 Annual Report. Cancer

VASCULOCIS 10 mg kit for radiopharmaceutical preparation

Indium-111 Zevalin Imaging

PHYSICAL CHARACTERISTICS

Endocrine System WHO IS IN CONTROL?

Biology Anatomy and Physiology I. Learn and Understand. What is Biology? bios = life -ology = study of

ICRP Recommendations Evolution or Revolution? John R Cooper Main Commission

MONTE CARLO SIMULATIONS FOR HOMELAND SECURITY USING ANTHROPOMORPHIC PHANTOMS. A Thesis Presented to The Academic Faculty.

Ryan Niederkohr, M.D. Slides are not to be reproduced without permission of author

GASTRIC EMPTYING STUDY (SOLID)

SUMMARY OF PRODUCT CHARACTERISTICS. for

The Endocrine System PART B

CS 6824: Tissue-Based Map of the Human Proteome

Option D: Medicinal Chemistry

Overview of Anatomy & Physiology

Transcription:

Whole-body biodistribution and radiation dosimetry estimates for the β-amyloid radioligand [ 11 C]MeS-IMPY in non-human primates Molecular Imaging Branch, NIMH Bldg. 1 Rm. B3-10 September 6 th, 2006

The following report presents measurements of whole-body biodistribution over time of [ 11 C]MeS- IMPY and estimation of resulting radiation exposure to organs of the body. Absorbed doses were estimated following administration of [ 11 C]MeS-IMPY and calculated from rhesus monkey biodistribution data. Radioactivity distribution Two male rhesus monkeys (5.25 and 5.95 kg) underwent whole-body PET scans after intravenous injection via the posterior tibial vein of 6.77 and 9.95 mci of [ 11 C]MeS-IMPY. 2D dynamic scans were acquired on the GE Advance tomography (GE Medical Systems, WI) in 4 segments of the body (head to upper thigh) in frames of increasing duration (75 s to 15 min) for a total scan time of 120 minutes. The tomographic PET images were compressed into a single planar image. Image analysis was done using the PMOD 2.6 computer program on the compressed planar images. Regions of interest (ROIs) were drawn in source organs that could be identified: brain, heart, liver, gallbladder, lungs, kidneys, and urinary bladder. Large ROIs were placed to assure that all accumulated radioactivity in each organ was encompassed. Many of the source organs were not confined to a single bed position. In these cases, new time points were generated for these organs to correspond with the activity data. This was achieved by weighting the time points associated with each bed position the organ appeared in by the percentage of the organ volume present in a given section. These values were then summed to give the final time points. The organ values of IA were corrected for recovery of measured activity. To accomplish this, a large region of interest was placed over the entire body for each of the 22 frames. The IA value for each source organ at every time point was corrected for recovery by multiplying by 100/X, where X is the measured recovery for the individual frame. The remainder of body was calculated for each time point as the decayed value of the original IA minus activity present in the identified source organs. Calculating Residence Times At each time point, non-decay-corrected data of those organs were converted to the fraction of the injected dose by dividing the organ activities by the total injected activity (IA). The total injected activity was calculated as the entire activity present in frame 1 in each of the four segments. Time-activity curves (TACs) for the source organs are shown in Figures 1 to 8. The area under the curve of each organ was calculated by the trapezoidal method up to the termination of acquisition (120 min). The area under the curve after the acquisition of the last image, i.e., to infinity, was calculated by assuming that the decline in radioactivity after this time point occurred by only physical decay, without any further biological clearance. The area under the curve of % injected activity from time zero to infinity (after multiplication by 100) is equivalent to residence time for the monkey. The residence times from the monkey were converted into corresponding human values by multiplication with a factor to scale organ and body weights: (b m /o m ) x (b h /o h ), where b m and b h are the body weights of monkey and human, respectively; and o m and o h are the organ weights of monkey and human, respectively. Table 1 gives the average residence time for each of the source organs and for the remainder of the body. Estimation of human absorbed radiation dose The radiation absorbed doses were calculated by entering the residence times for all source organs into OLINDA 1.0 computer program using the model for a 70-kg adult male. Table 2 shows the absorbed dose estimates for humans.

Table 1. Human residence times for [ 11 C]MeS-IMPY extrapolated from two rhesus monkeys calculated from whole-body planar images. Residence time (h) Monkey Organ 1 2 Brain 0.017 0.008 Heart 0.003 0.005 Liver 0.074 0.038 Gallbladder 0.014 0.012 Lung 0.040 0.053 Bladder 0.020 0.030 Kidney 0.007 0.016 Remainder 0.240 0.320

Table 2. Radiation dosimetry estimates for [ 11 C]MeS-IMPY extrapolated from the mean of the two monkey data estimated for human (Dynamic urinary bladder model was used, based on 2.4 h voiding interval). Organ μsv/mbq mrem/mci Adrenals 3.06 11.30 Brain 3.17 11.71 Breasts 1.91 7.05 Gallbladder Wall 33.15 122.50 LLI Wall 2.34 8.66 Small Intestine 2.50 9.22 Stomach 2.42 8.96 ULI Wall 2.63 9.71 Heart Wall 4.99 18.45 Kidneys 11.62 42.95 Liver 10.54 39.05 Lungs 12.80 47.35 Muscle 2.06 7.61 Ovaries 2.43 9.01 Pancreas 3.06 11.30 Red Marrow 1.98 7.33 Osteogenic Cells 2.81 10.38 Skin 1.59 5.87 Spleen 2.37 8.78 Testes 1.91 7.05 Thymus 2.24 8.28 Thyroid 1.92 7.11 Urinary Bladder Wall 16.70 61.75 Uterus 2.81 10.39 Total Body 2.55 9.43 Effective Dose Equivalent 7.43 27.50 Effective Dose 4.61 17.05

%Injected Activity 12 10 8 6 4 2 Brain Heart Liver GB Lungs Kidneys Bladder 0 0 20 40 60 80 100 120 Time (min) Figure 1. Mean organ uptake over time without decay correction, expressed as a percentage of injected activity of [ 11 C]MeS-IMPY on planar images.

Brain %Injected Activity 4 3 2 1 Brain 0 0 20 40 60 80 100 120 Time (min) Figure 2. Time-activity curve for [ 11 C]MeS-IMPY as determined by PET imaging of brain. Data are expressed as the average of two monkeys and without decay correction.

Heart %Injected Activity 2.5 2.0 1.5 1.0 0.5 Heart 0.0 0 20 40 60 80 100 120 Time (min) Figure 3. Time-activity curve for [ 11 C]MeS-IMPY as determined by PET imaging of heart. Data are expressed as the average of two monkeys and without decay correction.

Liver %Injected Activity 12 10 8 6 4 2 Liver 0 0 20 40 60 80 100 120 Time (min) Figure 4. Time-activity curve for [ 11 C]MeS-IMPY as determined by PET imaging of liver. Data are expressed as the average of two monkeys and without decay correction.

Gallbladder 1.5 Gallbladder %Injected Activity 1.0 0.5 0.0 0 20 40 60 80 100 120 Time (min) Figure 5. Time-activity curve for [ 11 C]MeS-IMPY as determined by PET imaging of gallbladder. Data are expressed as the average of two monkeys and without decay correction.

Lungs %Injected Activity 14 12 10 8 6 4 2 Lungs 0 0 20 40 60 80 100 120 Time (min) Figure 6. Time-activity curve for [ 11 C]MeS-IMPY as determined by PET imaging of lungs. Data are expressed as the average of two monkeys and without decay correction.

Kidneys 5 Kidneys %Injected Activity 4 3 2 1 0 0 20 40 60 80 100 120 Time (min) Figure 7. Time-activity curve for [ 11 C]MeS-IMPY as determined by PET imaging of kidneys. Data are expressed as the average of two monkeys and without decay correction.

Bladder 2.5 Bladder %Injected Activity 2.0 1.5 1.0 0.5 0.0 0 20 40 60 80 100 120 Time (min) Figure 8. Time-activity curve for [ 11 C]MeS-IMPY as determined by PET imaging of bladder. Data are expressed as the average of two monkeys and are non-corrected for radioactive decay.

Fraction injected activity 0.15 0.10 0.05 0.00 0.0 0.5 1.0 1.5 2.0 Time (h) Figure 9. Time-activity curve for [ 11 C]MeS-IMPY as determined by PET imaging of urinary bladder. Data are expressed as the average of two monkeys and are corrected for radioactive decay. Solid line overlying the measured data points represents a biexponential fitting with an asymptote of 15% of urine activity in bladder at infinite time.

Appendix A

Appendix B Whole-body images demonstrating biodistribution of [ 11 C]MeS-IMPY in monkey 1 at 1, 25, and 105 min after radioligand injection. 1 min 25 min 105 min

Appendix C [ 11 C]MeS-IMPY RADIATION DOSIMETRY (USING MONKEY 1 RESIDENCE TIMES) OLINDA - Organ Level Internal Dose Assessment Code (Vanderbilt University, 2003) NOTE: This code gives doses for stylized models of average individuals - results should be applied with caution to specific human subjects. NOTE: Users should always carefully check input data (shown below) and critically review the reported results. Organ Doses (msv/mbq), Nuclide: C-11 (1.22E03 sec), Adult Male Target Organ Alpha Beta Photon Total EDE Cont. ED Cont. Adrenals 0.00E000 7.22E-04 2.19E-03 2.91E-03 0.00E000 1.45E-05 Brain 0.00E000 2.66E-03 1.49E-03 4.14E-03 0.00E000 2.07E-05 Breasts 0.00E000 7.22E-04 9.72E-04 1.69E-03 2.54E-04 8.47E-05 GB Wall 0.00E000 2.83E-02 7.33E-03 3.56E-02 2.14E-03 0.00E000 LLI Wall 0.00E000 7.22E-04 2.30E-03 3.02E-03 0.00E000 3.63E-04 Small Int. 0.00E000 7.22E-04 1.89E-03 2.62E-03 0.00E000 1.31E-05 Stomach Wall 0.00E000 7.22E-04 1.51E-03 2.23E-03 0.00E000 2.68E-04 ULI Wall 0.00E000 7.22E-04 1.99E-03 2.71E-03 0.00E000 1.35E-05 Heart Wall 0.00E000 2.11E-03 1.98E-03 4.09E-03 0.00E000 0.00E000 Kidneys 0.00E000 5.17E-03 2.54E-03 7.70E-03 4.62E-04 3.85E-05 Liver 0.00E000 8.60E-03 4.87E-03 1.35E-02 8.08E-04 6.73E-04 Lungs 0.00E000 8.87E-03 2.27E-03 1.11E-02 1.34E-03 1.34E-03 Muscle 0.00E000 7.22E-04 1.35E-03 2.07E-03 0.00E000 1.04E-05 Ovaries 0.00E000 7.22E-04 2.31E-03 3.03E-03 7.58E-04 6.06E-04 Pancreas 0.00E000 7.22E-04 2.19E-03 2.91E-03 0.00E000 1.46E-05 Red Marrow 0.00E000 5.14E-04 1.42E-03 1.94E-03 2.33E-04 2.33E-04 Osteogenic Ce 0.00E000 1.27E-03 1.30E-03 2.57E-03 7.72E-05 2.57E-05 Skin 0.00E000 7.22E-04 7.64E-04 1.49E-03 0.00E000 1.49E-05 Spleen 0.00E000 7.22E-04 1.36E-03 2.08E-03 0.00E000 1.04E-05 Testes 0.00E000 7.22E-04 1.58E-03 2.31E-03 0.00E000 0.00E000 Thymus 0.00E000 7.22E-04 1.24E-03 1.96E-03 0.00E000 9.81E-06 Thyroid 0.00E000 7.22E-04 9.60E-04 1.68E-03 5.05E-05 8.41E-05 Bladder Wall 0.00E000 4.80E-02 1.41E-02 6.22E-02 3.73E-03 3.11E-03 Uterus 0.00E000 7.22E-04 3.88E-03 4.61E-03 2.76E-04 2.30E-05 Total Body 0.00E000 1.18E-03 1.43E-03 2.61E-03 0.00E000 0.00E000 Effective Dose Equivalent (msv/mbq): 1.01E-02 Effective Dose (msv/mbq): 6.97E-03 Organ Doses (rem/mci), Nuclide: C-11 (1.22E03 sec), Adult Male Target Organ Alpha Beta Photon Total EDE Cont. ED Cont. Adrenals 0.00E000 2.67E-03 8.09E-03 1.08E-02 0.00E000 5.38E-05 Brain 0.00E000 9.83E-03 5.50E-03 1.53E-02 0.00E000 7.66E-05 Breasts 0.00E000 2.67E-03 3.60E-03 6.27E-03 9.40E-04 3.13E-04 GB Wall 0.00E000 1.05E-01 2.71E-02 1.32E-01 7.90E-03 0.00E000 LLI Wall 0.00E000 2.67E-03 8.50E-03 1.12E-02 0.00E000 1.34E-03 Small Int. 0.00E000 2.67E-03 7.01E-03 9.68E-03 0.00E000 4.84E-05 Stomach Wall 0.00E000 2.67E-03 5.58E-03 8.26E-03 0.00E000 9.91E-04 ULI Wall 0.00E000 2.67E-03 7.35E-03 1.00E-02 0.00E000 5.01E-05 Heart Wall 0.00E000 7.79E-03 7.33E-03 1.51E-02 0.00E000 0.00E000 Kidneys 0.00E000 1.91E-02 9.38E-03 2.85E-02 1.71E-03 1.43E-04

Liver 0.00E000 3.18E-02 1.80E-02 4.98E-02 2.99E-03 2.49E-03 Lungs 0.00E000 3.28E-02 8.39E-03 4.12E-02 4.95E-03 4.95E-03 Muscle 0.00E000 2.67E-03 4.99E-03 7.67E-03 0.00E000 3.83E-05 Ovaries 0.00E000 2.67E-03 8.54E-03 1.12E-02 2.80E-03 2.24E-03 Pancreas 0.00E000 2.67E-03 8.10E-03 1.08E-02 0.00E000 5.39E-05 Red Marrow 0.00E000 1.90E-03 5.27E-03 7.17E-03 8.60E-04 8.60E-04 Osteogenic Ce 0.00E000 4.71E-03 4.81E-03 9.52E-03 2.85E-04 9.52E-05 Skin 0.00E000 2.67E-03 2.83E-03 5.50E-03 0.00E000 5.50E-05 Spleen 0.00E000 2.67E-03 5.01E-03 7.69E-03 0.00E000 3.84E-05 Testes 0.00E000 2.67E-03 5.86E-03 8.53E-03 0.00E000 0.00E000 Thymus 0.00E000 2.67E-03 4.59E-03 7.26E-03 0.00E000 3.63E-05 Thyroid 0.00E000 2.67E-03 3.55E-03 6.22E-03 1.87E-04 3.11E-04 Bladder Wall 0.00E000 1.78E-01 5.22E-02 2.30E-01 1.38E-02 1.15E-02 Uterus 0.00E000 2.67E-03 1.44E-02 1.70E-02 1.02E-03 8.52E-05 Total Body 0.00E000 4.37E-03 5.28E-03 9.66E-03 0.00E000 0.00E000 Effective Dose Equivalent (rem/mci): 3.74E-02 Effective Dose (rem/mci): 2.58E-02 Number of Disintegrations in Source Organs: Adrenals Brain 1.70E-02 MBq-h/MBq or uci-h/uci Breasts Gallbladder Contents 1.40E-02 MBq-h/MBq or uci-h/uci LLI Small Intestine Stomach ULI Heart Contents Heart Wall 3.00E-03 MBq-h/MBq or uci-h/uci Kidneys 7.00E-03 MBq-h/MBq or uci-h/uci Liver 7.40E-02 MBq-h/MBq or uci-h/uci Lungs 4.00E-02 MBq-h/MBq or uci-h/uci Muscle Ovaries Pancreas Red Marrow Cortical Bone Trabecular Bone Spleen Testes Thymus Thyroid Urinary Bladder Contents 9.00E-02 MBq-h/MBq or uci-h/uci Uterus/Uterine Wall Remainder 2.40E-01 MBq-h/MBq or uci-h/uci Target Organ Masses: Adrenals Brain Breasts Gallbladder Wall LLI Wall Small Intestine Stomach Wall ULI Wall Heart Wall Kidneys 1.63E001 g 1.42E003 g 3.51E002 g 1.05E001 g 1.67E002 g 6.77E002 g 1.58E002 g 2.20E002 g 3.16E002 g 2.99E002 g

Liver Lungs Muscle Ovaries Pancreas Red Marrow Osteogenic Cells Skin Spleen Testes Thymus Thyroid Urinary Bladder Wall Uterus Total Body 1.91E003 g 1.00E003 g 2.80E004 g 8.71E000 g 9.43E001 g 1.12E003 g 1.20E002 g 3.01E003 g 1.83E002 g 3.91E001 g 2.09E001 g 2.07E001 g 4.76E001 g 7.90E001 g 7.37E004 g * Mass modified by user Radiation Weighting Factors: Alpha: 5.00E00 Beta: 1.00E00 Photon: 1.00E00 ** Weighting factor modified by user

Appendix D Weights of rhesus monkey 1 and human organs 2 (kg). Weight(kg ) Organ Monkey Human Brain 0.087 1.450 Heart 0.027 0.280 Liver 0.144 1.810 Lung 0.052 0.999 Kidney 0.024 0.284 Total body 6.0 69.9 Remainder 5.77 63.82 References 1. Bourne GH (1975) The Rhesus monkey. Academic Press, Academic Press 2. Venes D, Taber CW (2005) Taber's cyclopedic medical dictionary, Ed. 20, illustrated in full color / edn. F.A. Davis Co., F.A. Davis Co.